Literature DB >> 17301836

Chromosomal translocations as a mechanism of BRAF activation in two cases of large congenital melanocytic nevi.

Barbara Dessars1, Linda E De Raeve, Hakim El Housni, Catherine J Debouck, Pierre J Sidon, Renato Morandini, Diane Roseeuw, Ghanem E Ghanem, Gilbert Vassart, Pierre Heimann.   

Abstract

Genetic studies of melanocytic tumors have mainly demonstrated activation of oncogenes such as NRAS or BRAF through point mutations. In two cases of large congenital melanocytic nevi, we observed a chromosomal translocation involving the BRAF oncogene on chromosome 7q34, resulting in both cases in removal of the auto-inhibitory N-terminal regulatory domain (hence the Ras-guanosine triphosphate binding domain) of BRAF from its protein kinase domain. This is early evidence of BRAF activation through chromosomal translocation in melanocytic tumors. Because BRAF point mutations are rather rare in congenital melanocytic nevi and melanoma arising in non-sun-exposed area, the molecular mechanism of oncogenic activation as described here could be a recurrent molecular feature in these groups of melanocytic tumors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17301836     DOI: 10.1038/sj.jid.5700725

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  19 in total

1.  Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma.

Authors:  Nallasivam Palanisamy; Bushra Ateeq; Shanker Kalyana-Sundaram; Dorothee Pflueger; Kalpana Ramnarayanan; Sunita Shankar; Bo Han; Qi Cao; Xuhong Cao; Khalid Suleman; Chandan Kumar-Sinha; Saravana M Dhanasekaran; Ying-bei Chen; Raquel Esgueva; Samprit Banerjee; Christopher J LaFargue; Javed Siddiqui; Francesca Demichelis; Peter Moeller; Tarek A Bismar; Rainer Kuefer; Douglas R Fullen; Timothy M Johnson; Joel K Greenson; Thomas J Giordano; Patrick Tan; Scott A Tomlins; Sooryanarayana Varambally; Mark A Rubin; Christopher A Maher; Arul M Chinnaiyan
Journal:  Nat Med       Date:  2010-06-06       Impact factor: 53.440

2.  Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.

Authors:  H S Kim; M Jung; H N Kang; H Kim; C-W Park; S-M Kim; S J Shin; S H Kim; S G Kim; E K Kim; M R Yun; Z Zheng; K Y Chung; J Greenbowe; S M Ali; T-M Kim; B C Cho
Journal:  Oncogene       Date:  2017-01-16       Impact factor: 9.867

3.  Neurocutaneous melanocytosis (melanosis).

Authors:  Martino Ruggieri; Agata Polizzi; Stefano Catanzaro; Manuela Lo Bianco; Andrea D Praticò; Concezio Di Rocco
Journal:  Childs Nerv Syst       Date:  2020-10-13       Impact factor: 1.475

Review 4.  Unclassified sclerosing malignant melanomas with AKAP9-BRAF gene fusion: a report of two cases and review of BRAF fusions in melanocytic tumors.

Authors:  Emilie Perron; Daniel Pissaloux; Angela Neub; Daniel Hohl; Marie Dominique Tartar; Laurent Mortier; Laurent Alberti; Arnaud de la Fouchardiere
Journal:  Virchows Arch       Date:  2018-02-21       Impact factor: 4.064

Review 5.  The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia.

Authors:  Boris C Bastian
Journal:  Annu Rev Pathol       Date:  2014       Impact factor: 23.472

6.  Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy.

Authors:  Thomas Botton; Iwei Yeh; Tyrrell Nelson; Swapna S Vemula; Alyssa Sparatta; Maria C Garrido; Maryline Allegra; Stephane Rocchi; Philippe Bahadoran; Timothy H McCalmont; Philip E LeBoit; Elizabeth A Burton; Gideon Bollag; Robert Ballotti; Boris C Bastian
Journal:  Pigment Cell Melanoma Res       Date:  2013-08-19       Impact factor: 4.693

7.  BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.

Authors:  Katherine E Hutchinson; Doron Lipson; Philip J Stephens; Geoff Otto; Brian D Lehmann; Pamela L Lyle; Cindy L Vnencak-Jones; Jeffrey S Ross; Jennifer A Pietenpol; Jeffrey A Sosman; Igor Puzanov; Vincent A Miller; William Pao
Journal:  Clin Cancer Res       Date:  2013-12-15       Impact factor: 12.531

8.  BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas.

Authors:  Stefan Pfister; Wibke G Janzarik; Marc Remke; Aurélie Ernst; Wiebke Werft; Natalia Becker; Grischa Toedt; Andrea Wittmann; Christian Kratz; Heike Olbrich; Rezvan Ahmadi; Barbara Thieme; Stefan Joos; Bernhard Radlwimmer; Andreas Kulozik; Torsten Pietsch; Christel Herold-Mende; Astrid Gnekow; Guido Reifenberger; Andrey Korshunov; Wolfram Scheurlen; Heymut Omran; Peter Lichter
Journal:  J Clin Invest       Date:  2008-05       Impact factor: 14.808

Review 9.  MAPK pathway activation in pilocytic astrocytoma.

Authors:  David T W Jones; Jan Gronych; Peter Lichter; Olaf Witt; Stefan M Pfister
Journal:  Cell Mol Life Sci       Date:  2011-12-13       Impact factor: 9.261

10.  Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas.

Authors:  David T W Jones; Sylvia Kocialkowski; Lu Liu; Danita M Pearson; L Magnus Bäcklund; Koichi Ichimura; V Peter Collins
Journal:  Cancer Res       Date:  2008-11-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.